🇺🇸 FDA
Patent

US 8147833

Prevention and treatment of synucleinopathic and amyloidogenic disease

granted A61KA61K2039/505A61K2039/55566

Quick answer

US patent 8147833 (Prevention and treatment of synucleinopathic and amyloidogenic disease) held by The Regents of the University of California expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K2039/505, A61K2039/55566, A61K2039/575, A61K39/0007